Cargando…
Advances in Antisense Oligonucleotide Development for Target Identification, Validation, and as Novel Therapeutics
Antisense oligonucleotides (As-ODNs) are single stranded, synthetically prepared strands of deoxynucleotide sequences, usually 18–21 nucleotides in length, complementary to the mRNA sequence of the target gene. As-ODNs are able to selectively bind cognate mRNA sequences by sequence-specific hybridiz...
Autores principales: | Mansoor, Moizza, Melendez, Alirio J. |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Libertas Academica
2008
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2733095/ https://www.ncbi.nlm.nih.gov/pubmed/19787090 |
Ejemplares similares
-
Making Sense of Antisense Oligonucleotide Therapeutics Targeting Bcl-2
por: Gagliardi, Maria, et al.
Publicado: (2022) -
Therapeutic Potential of Tricyclo-DNA antisense oligonucleotides
por: Goyenvalle, Aurelie, et al.
Publicado: (2016) -
Nonviral delivery systems for antisense oligonucleotide therapeutics
por: Huang, Si, et al.
Publicado: (2022) -
Antisense Oligonucleotides Targeting Angiogenic Factors as Potential Cancer Therapeutics
por: Le, Bao T., et al.
Publicado: (2018) -
Antisense oligonucleotides in neurological disorders
por: Wurster, Claudia D., et al.
Publicado: (2018)